BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Crucell N.V. (CRXL) And DSM Announce PER.C6(R) Licensing And Service Agreement With Roche (RHHBY) For Protein Production


10/19/2005 5:12:44 PM

LEIDEN, The Netherlands, Feb. 16, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6(R) research license agreement with Roche. This license agreement allows Roche to use the PER.C6(R) cell line for production of monoclonal antibody products as well as a specific undisclosed protein.Roche has selected PER.C6(R) for this particular protein because it believes PER.C6(R) possesses unique features capable of delivering the appropriate product quality. Further to this agreement, Crucell will work with Roche in creating a production clone for the specific protein.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->